Compound from rare plant shows promise in treating breast cancer
They started with a bare room and an idea. Now, after five years of painstaking, sophisticated tests, scientists at the University of Virginia Health System have discovered that a compound, derived from a rare South American plant, stops the growth of human breast cancer cells in laboratory cultures.
U. Va. Health System scientists Deborah Lannigan and Jeffrey Smith hope that, after further testing, their discovery could translate into a successful drug for the treatment of breast cancer. The disease is the second leading cancer killer of women in the U.S., according to the American Cancer Society, with an estimated 40,410 deaths.
The compound, called SL0101, comes from the plant Forsteronia refracta, a nondescript member of the dogbane family found in the Amazonian rain forest. The compound works like a key in a molecular lock. It inhibits the action of a cancer-linked protein called RSK, which the researchers discovered is important for controlling the growth of breast cancer cells. Interestingly, SL0101 does not alter the growth of normal breast cells. The discovery is detailed in the Feb. 1, 2005 issue of the journal Cancer Research and can be found online at: www.cancerres.aacrjournals.org.
"By preventing RSK from working, we completely stopped the growth of breast cancer cells but did not affect the growth of normal breast cells," said Lannigan, an Assistant Professor of Microbiology at the U. Va. Cancer Center. She compares this discovery to the development of the drug Gleevec for the treatment of chronic myeloid leukemia. Like Gleevec, SL0101 is a signal transduction inhibitor that interferes with the pathways that signal the growth of tumors. "Gleevec is an exciting discovery and were hoping to have similar success with SL0101," Lannigan said.
For now, Lannigan and Smith have begun testing the compound in animal models. "The next step is to see if SL0101 will prevent the growth of human tumor cells in mice," said Smith, a Research Assistant Professor of Pathology at the U.Va. Cancer Center. "We will modify the structure of SL0101, if necessary, to eventually find a compound that can be carried through to human clinical trials. Thats the goal. But human trials will likely be years down the road." The discovery of this potential anti-cancer compound at a U.Va. lab, Lannigan said, also highlights the important role of academic research in drug development.
The researchers collaborated on this discovery with a U.Va. Professor of Chemistry, Dr. Sidney Hecht, who maintains a large number of exotic plants collected by the National Cancer Institute in the 1960s for research purposes. It took years of work to identify and characterize SL0101 as a specific RSK inhibitor. "Finding out that RSK is a good drug target for breast cancer is very exciting," Smith said.
Cancer patients themselves can also take credit for this discovery. A group of volunteers from "Patients and Friends of the U.Va. Cancer Center" provided funds at a crucial stage of the research.
Bob Beard | EurekAlert!
The most recent press releases about innovation >>>
Die letzten 5 Focus-News des innovations-reports im Überblick:
Physicists have developed a new technique that uses electrical voltages to control the electron spin on a chip. The newly-developed method provides protection from spin decay, meaning that the contained information can be maintained and transmitted over comparatively large distances, as has been demonstrated by a team from the University of Basel’s Department of Physics and the Swiss Nanoscience Institute. The results have been published in Physical Review X.
For several years, researchers have been trying to use the spin of an electron to store and transmit information. The spin of each electron is always coupled...
What is the mass of a proton? Scientists from Germany and Japan successfully did an important step towards the most exact knowledge of this fundamental constant. By means of precision measurements on a single proton, they could improve the precision by a factor of three and also correct the existing value.
To determine the mass of a single proton still more accurate – a group of physicists led by Klaus Blaum and Sven Sturm of the Max Planck Institute for Nuclear...
A bacterial enzyme enables reactions that open up alternatives to key industrial chemical processes
The research team of Prof. Dr. Oliver Einsle at the University of Freiburg's Institute of Biochemistry has long been exploring the functioning of nitrogenase....
Larsen C Ice Shelf rift finally breaks through
A one trillion tonne iceberg - one of the biggest ever recorded -- has calved away from the Larsen C Ice Shelf in Antarctica, after a rift in the ice,...
Physics supports biology: Researchers from PTB have developed a model system to investigate friction phenomena with atomic precision
Friction: what you want from car brakes, otherwise rather a nuisance. In any case, it is useful to know as precisely as possible how friction phenomena arise –...